Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CV Therapeutics, Inc.

http://www.cvt.com

Latest From CV Therapeutics, Inc.

Russia-Ukraine War Likely To Claim Sputnik V Partners As Casualty

In light of the Russia-Ukraine conflict, Scrip looks at data to gauge if manufacturing partners for COVID-19 vaccine Sputnik V or Light, in India, China and Korea could be left holding unsold inventory earmarked for exports

Commercial Coronavirus COVID-19

Intas And Axantia Ink Middle East Ranibizumab Distribution Deal

Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.

Deals Biosimilars

Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.

Clinical Trials Business Strategies

MeMed Secures $93M Financing To Commercialize Diagnostics Platform

The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.

Diagnostics Financing
See All

Company Information

UsernamePublicRestriction

Register